A study  published in JAMA Network Open  examined pharmacy barriers faced by patients prescribed buprenorphine to treat opioid use disorder (OUD) through telemedicine. The findings show that pharmacy-related challenges were common, with nearly one-third of study participants (31.9%) reporting going without buprenorphine at some point in the prior 12 months due to pharmacy-related barriers. Researchers surveyed 601 adults who were receiving treatment from a multistate telemedi

A randomized clinical trial published in JAMA Network Open  found that incorporating online group mindfulness sessions into buprenorphine treatment for opioid use disorder (OUD) significantly reduced opioid cravings compared to treatment as usual. The study, led by Dr. Zev Schuman-Olivier and colleagues from Cambridge Health Alliance and Harvard Medical School, examined the effectiveness of a 24-week virtual mindfulness-based program compared to a standard recovery support gr

A new report  from the Substance Abuse and Mental Health Services Administration (SAMHSA) on  Treatment Episode Data Set (TEDS) provides a detailed snapshot of substance use disorder treatment services across the United States. Findings are drawn from nearly 1.5 million treatment admissions and 1.4 million discharges reported in 2022 and show that 35.5% of admissions were for alcohol use, 16.9% were for heroin use, 13.9% were for methamphetamine use, 11.7% were for other opia

The Substance Use and Mental Health Services Administration (SAMHSA) announced updated guidelines  that expand the incentive cap for...

CDC data shows a 10% drop in overdose deaths this year.

As the opioid crisis continues to devastate communities across the United States, claiming thousands of lives each year, the HEALing...

Effective treatments for substance use disorder (SUD) can substantially improve patient outcomes. First-line medications like...

Data dashboards are powerful tools that can support community engagement and decision-making by providing public health surveillance and...

In the United States, at least one infant is born with Neonatal Opioid Withdrawal Syndrome (NOWS) every 24 minutes. Opioid-exposed...

Peer distribution of naloxone and education on its use enhances partnerships between medical researchers, law enforcement, public health...

In Hamilton County, Ohio, 76% of the people who overdosed in 2021 had a history of incarceration at the Hamilton County Justice Center...

There has been a substantial increase in the number of jails and prisons offering medications for opioid use disorder (MOUD; namely,...

This webinar, held by Addiction Policy Forum, discussed recent data on the impact of fentanyl on communities across the country, and new...

Findings from the Eating, Sleeping and Consoling for Neonatal Opioid Withdrawal study show a new care approach that is more effective

Medications for opioid use disorder Medications used to treat opioid use disorders are considered the “gold standard” of treatment....

Fentanyl and other high-potency synthetic opioids are increasingly present in the U.S. drug supply. Healthcare systems, treatment...

APF Executive Director Jessica Hulsey spoke before a Joint meeting of the Nonprescription Drugs and the Anesthetic and Analgesic Drug...

24 Strategies for State, County and City Implementation Addiction Policy Forum’s report, Evidence-Based Interventions to Address the...

The Opioid Prevention Campaign is a public health media campaign to help prevent adolescent substance use.

New OUD research summarized for helps officials, practitioners, families, patients, and communities